Cancer Research Technology Limited

Justin Bower

Mairi Sime

Simone Belshaw

Stuart Francis

Angelo Pugliese

Duncan McArthur

Provided are compounds of the Formula (I), and salts and solvates thereof: (Formula (I)) wherein R, R, X, L, A, R, Rand Z are defined in the specification. The compounds are inhibitors of salt-inducible kinase (SIK), particular SIK2, and are useful in therapy, particularly in the treatment of a proliferative disorder, a benign neoplasm, pathological angiogenesis, an inflammatory disease or condition, a musculoskeletal disease or condition, an autoimmune disease, a haematological disease or condition, a neurological disease or condition, a psychiatric disorder, or a metabolic disorder.

Bicyclic nitrogen containing heterocycles as inhibitors of salt-induced kinase SIK2

The present application relates to a compound of Formula I, or a salt, hydrate or solvate thereof, as defined herein. The present compounds are found to have pharmacological effects, particularly at MRCK. Further provided are pharmaceutical compositions comprising said compounds. The present invention also relates to the use of these compounds as therapeutic agents, in particular, for the treatment and/or prevention of proliferative diseases, such as cancer.

Growing community of inventors

Glasgow, United Kingdom

Justin Bower